Flanagan W. Michael 4

What Happened

• W. Michael Flanagan, a director of Atrium Therapeutics (RNA), was granted a derivative award covering 20,000 shares on February 27, 2026. The Form 4 reports the acquisition value as $0.00, consistent with an equity award/option grant rather than a cash purchase or sale.

Key Details

• Transaction date and type: 2026-02-27 — Grant/Award (derivative).
• Quantity and reported price: 20,000 shares (derivative) at $0.00 reported.
• Vesting: Per the filing footnote, the shares underlying the options vest in equal monthly installments over the three years following the grant date, subject to the reporting person’s continuous service.
• Ownership after transaction: Not specified in the provided filing details.
• Filing: Form 4 filed March 2, 2026 (no late filing flag shown in the supplied information).

Context

• This was an equity award (options/derivative), a common form of executive/director compensation. The Form 4 does not show exercise/strike price or indicate any immediate sale of shares; economic value depends on the option terms and future stock price. Grants are routine and do not by themselves indicate insider buying or selling sentiment.